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012.05.0Abstract Background: Missing thrombolytic therapy in patients with acute ST-elevation myocar-
dial infarction (STEMI) can have dire consequences. We studied the prevalence and causes of fail-
ure of receiving thrombolytic therapy in patients with STEMI and its impact on the clinical
outcome during hospitalization.
Patients and methods: This was an observational, analytic, cross sectional study carried out in the
CCU and emergency departments of three public hospitals in Port Said, Egypt. We interrogated all
patients admitted within 72 h of possible acute coronary syndrome and only patients proved to have
STEMI as deﬁned by the updated ACC criteria were analyzed for receiving thrombolytic therapy or
not. All STEMI patients were subjected to: medical history taking, thorough clinical examination,
12-leads surface electrocardiography, cardiac biomarkers (troponin I), and predischarge trans-tho-
racic echocardiography.
Results: Of 6522 patients screened, only 288 patients had STEMI. The prevalence of missed throm-
bolysis in these patients was 45%. Delayed presentation after the onset of symptoms represented the
most common cause for failure to receive thrombolysis (54% of the cases), while misdiagnosis at the
emergency department represented 35% of the cases. Female gender, diabetes mellitus and inferior
location of myocardial infarction were independent predictors of missed thrombolytic therapy. Car-
diac death, clinical heart failure and signiﬁcant cardiac dysrhythmias were higher in patients who
missed thrombolysis than in those who received it.
Conclusion: In this study, up to 45% of patients with STEMI missed the opportunity to receive
thrombolysis, most likely due to delayed presentation or misdiagnosis at the emergency department.
Patients with missed thrombolysis were at higher risk of cardiac death, clinical heart failure, and
hemodynamically signiﬁcant cardiac dysrhythmias.
ª 2012 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.106178663.
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021. Introduction
Acute myocardial infarction is a major cause of morbidity and
mortality in our general population. It results from prolonged
myocardial ischemia, precipitated in most cases by occlusiveg by Elsevier B.V. All rights reserved.
Table 1 Baseline clinical characteristics of the study
population.
Item Missed thrombolysis Received thrombolysis P-value
Age (years) 49.5 ± 28.6 45.7 ± 23.4 0.06
Gender (M/F) 88/42 60/98 0.05
Smoking 73(56.2%) 120(64.8%) 0.07
DM 73(56.2%) 90(48.6%) <0.05
Hypertension 68 (52.3%) 110(59.4%) 0.06
Dyslipidemia 122(93.8%) 120(64.8%) 0.09
Obesity 70(53.8%) 116(62.7%) 0.06
52 R. Taha et al.thrombus at the site of a pre-existing atheromatous plaque.
Prompt reperfusion of an obstructed coronary artery by either
thrombolytic therapy or primary angioplasty can limit
myocardial necrosis, improve myocardial salvage, and reduce
mortality.1
Thrombolytic therapy in STEMI is generally safe and
effective. It is most effective if given within the ﬁrst 1.5 h after
the onset of symptoms.2 In one study, the greatest relative dif-
ference in mortality was seen in a small number of the patients
treated within the ﬁrst hour after the symptom onset with a
reduction in mortality and in almost 40% of the patients
aborting infarction process, thus preventing irreversible
myocardial damage and dysfunction.3 Collectively the large
trials of thrombolytic therapy demonstrated a 25% reduction
in 30-day mortality in patients received thrombolytic therapy
within 6 h of the onset of symptoms.4
Patients who are missing thrombolytic therapy are an unfor-
tunate group of high risk patients at higher risk of subsequent
cardiac events including death, heart failure and life-threaten-
ing arrhythmia.5 We undertook this study to determine the
prevalence of missing thrombolytic therapy in patients with
STEMI, to identify factors related to this failure, and to analyze
the clinical outcome of these patients compared to those who
received thrombolytic therapy.
2. Methods
This was an observational, cross sectional, analytic study
targeting the emergency departments and cardiac care units
(CCU) of three general public hospitals in Port-Said city
during the period from September 2009 to March 2010. We
screened all patients admitted within 72 h of possible acute
coronary syndrome (ACS), while we included only patients
with STEMI who had no contraindication to thrombolytic
therapy at the time of presentation. Included patients were
subjected to medical history taking, thorough physical exami-
nation, serial 12-lead surface ECG recordings, serial troponin I
testing, and predischarge trans-thoracic echo-Doppler study.
Patients with STEMI were divided into two groups: (1) who
received thrombolytic treatment and (2) who did not receive
this therapy.
2.1. Diagnosis of STEMI
We applied the criteria proposed by The Joint American Col-
lege of Cardiology and European Society of Cardiology Com-
mittee for the deﬁnition of acute, evolving, or recent MI:
typical rise and gradual fall (troponin) or more rapid rise
and fall (Creatine kinase MB) of biochemical markers of
myocardial necrosis with at least one of the following: ischemic
symptoms, development of pathological Q wave on the ECG,
electrocardiographic changes indicative of ischemia, coronary
artery intervention, or pathologic ﬁnding of acute MI.
Established MI was deﬁned as any one criteria that satisﬁes
the following: development of new pathologic Q waves on
serial ECGs or pathologic ﬁnding of healed or healing MI.6
2.1.1. Echocardiography
Two dimensional echo-Doppler study was performed in all pa-
tients before discharge. Images performed in the standard par-
asternal and apical views with the patient in the left lateralposition. LV end-systolic and end-diastolic volumes were cal-
culated and EF estimated by modiﬁed Simpson technique.7
Regional LV systolic function was assessed according to the
16- segment model of the American Society of Echocardiogra-
phy and graded from 1 to 4 (1 – normal, 2 – hypokinesia, 3 –
akinesia, 4 – dyskinesia). Wall motion score index (WMSI) was
calculated by summing the score for each segment and divided
by the number of segments analyzed.8 Mechanical complica-
tions (including mitral incompetence, ventricular septal defect
and rupture myocardium) were also looked for and reported in
all patients.
2.1.2. Clinical outcome
In-hospital death, clinical heart failure, and signiﬁcant cardiac
dysrhythmias (including sustained and hemodynamically com-
promising dysrhythmias) were compared between the two
groups.
2.1.3. Statistical analysis
Data were analyzed on SPSS version 10.0. Rates of missed
thrombolysis were compared among groups of patients with
different demographic or clinical characteristics with the use
of chi-square tests for dichotomous variables and Fisher’s ex-
act tests for nominal variables. Logistic regression was used to
explore multivariate associations between different variables
and missing thrombolysis. A value of P< 0.05 was considered
signiﬁcant.
3. Results
We interrogated 6522 patients presented to the emergency
room because of possible ACS, 4259 patients proved to have
non-cardiac causes for chest pain and the remaining 2263 pa-
tients admitted as ACS patients. Of those who were admitted
with ACS, only 288 had STEMI with no contraindication to
thrombolytic therapy, of whom only 158 (55%) received
thrombolytic therapy by intravenous streptokinase comprising
group (1) while the remaining 130 (45%) patients missed this
therapy (group 2). Baseline clinical characteristics of both
groups are shown in Table 1.
Reasons for missing thrombolysis were: ﬁrst, the delayed
presentation to the emergency room (>24 h after the onset
of symptoms) in 59% of the cases, most likely because the pa-
tient had similar attacks of chest pain in the prior few days, va-
gue initial symptoms (e.g. dyspnea, nausea, and vomiting),
refusal of hospital admission at ﬁrst presentation, and living
far away from the hospital. Second, misdiagnosis at the emer-
Figure 1 Causes of missed thrombolysis in patients with
STEMI.
Table 2 Comparison of left ventricular systolic function in
patients who received thrombolysis versus those who missed
this therapy.
Ejection
fraction
Missed
thrombolysis
Received
thrombolysis
P-value
>55% 6(4.62%) 58(37%) <0.05
45–54% 7(5.38%) 48(31%)
30–44% 68(52.30%) 37(23%)
<30% 49(37.69%) 15(9%)
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tients missing thrombolysis were ﬁrst seen by the emergency
residents with only 14% seen by the cardiology specialists,
while 78% of patients received thrombolysis were ﬁrst seen
by cardiology specialists. Third, lack of availability of beds
in the CCU contributed to 6% of missed thrombolysis (Fig. 1).
Among patients with STEMI, only 85% had ECG record-
ings, and 12% had their cardiac enzymes checked at the timeTable 3 Comparison of diastolic function in patients who received
Missed thro
Normal 32(24.62%)
Mild dysfunction (slow ﬁlling pattern) 64(49.23%)
Moderate dysfunction (pseudonormal pattern) 25(19.23%)
Severe dysfunction (restrictive pattern) 9(6.92%)
Table 4 Clinical outcome in patients received thrombolysis versus
Complications Missed thrombolysis
Frequency %
Death 9 6
Heart failure 46 37
Arrhythmias 30 23of presentation. Patients with missed thrombolysis were more
likely to have inferior MI (42%) compared to patients who re-
ceived thrombolysis (28%) (P< 0.05).
Predischarge echocardiographic studies showed that
patients who received thrombolysis had better systolic and
diastolic functions (as measured by ejection fraction, and
trans-mitral pulsed-wave Doppler recordings, respectively)
than patients who missed thrombolysis, while WMSI was not
different among the two groups (Tables 2 and 3).
Patients with missed thrombolysis had higher adverse
in-hospital events including death, clinical heart failure and
cardiac dysrhythmias than patients who received this therapy
(Table 4). In addition, patients with missed thrombolysis had
longer hospital stay (6 ± 3 days) than patients who received
this therapy (4 ± 3 days) (P< 0.05).
4. Discussion
There is overwhelming evidence of the beneﬁcial effects
provided by reperfusion strategies in patients with STEMI,
however, thrombolytic therapy is still underused in the manage-
ment of this condition.9 We designed this study to deﬁne the
prevalence of missing thrombolytic therapy in STEMI, the
causes of this failure and its impact on the in-hospital clinical
outcome.
In this study the prevalence of missed thrombolytic therapy
in patients with STEMI was 45%, this is higher than that
reported by other investigators. In England the prevalence of
missed thrombolysis in men aged below 64 was 6.3%.10 In a
report of Heart Disease prevalence in United States, the prev-
alence of missed thrombolysis in patients with STEMI ranged
from 2.1% to 8.5%, and West Virginia had the highest preva-
lence.11 In Karachi (Pakistan) the prevalence of missed throm-
bolysis in STEMI was 32%, this relatively high prevalence was
explained in the light of the longer pre-hospital delay (median
24 h) in non-thrombolysed patients, due to living far away
from the health care providers and lack of fast transporta-
tion.12 More recently, Al-Mallah et al. found that 9.3% of
patients with STEMI did not receive reperfusion therapy de-
spite no contraindications; this study was carried out in six
Arab countries in the Gulf area as a part of Quality of Care
and Outcomes Assessment Program.13 This wide variation inthrombolysis versus those who missed this therapy.
mbolysis Received thrombolysis P-value
65(41%) <0.05
42(26.8%)
48(31%)
2(1.2%)
those who missed this therapy.
Received thrombolysis P-value
Frequency %
1 0.6 <0.05
15 9 <0.05
11 6 <0.05
54 R. Taha et al.the prevalence of missed thrombolytic therapy among our
study and different studies represents the difference in
socio-demographic and clinical characteristics of the studied
populations.
Delayed presentation to the emergency department (>24 h
after the onset of symptoms) represented the most likely cause
for missing thrombolytic opportunity (59% of the cases). Var-
ious causes for delayed presentation were encountered in this
study including: similar attacks of chest pain in the prior few
days, vague initial symptoms (e.g. dyspnea, nausea, and vom-
iting), refusal of hospital admission at ﬁrst presentation, and
living far away from the hospital. Consistent with this observa-
tion, Habib et al. reported delayed presentation to the emer-
gency room as the most common reason for missing
thrombolytic therapy.12
Misdiagnosis at the time of presentation to the emergency
room was the second common cause for missing thrombolysis
(35%). Previous studies had found that between 2% and 8%
of patients with acute myocardial infarction who presented
to the emergency department were misdiagnosed and sent
home.14–17 In our study, 86% of patients missing thrombolysis
were ﬁrst seen by the emergency residents with only 14% seen
by the cardiology specialists, while 78% of patients received
thrombolysis were ﬁrst seen by cardiology specialists. Failure
by the emergency department clinician to detect ST-segment
elevations of 1–2 mm in the electrocardiogram represented
an important cause for missing the diagnosis in our study
(44%). This incidence represents an important and potentially
preventable contribution to missing thrombolytic therapy.
We found that female gender, diabetes mellitus and inferior
location of myocardial infarction were all independent predic-
tors of missing thrombolytic therapy. Hector et al. reported
higher rates of misdiagnosis of myocardial infarction in wo-
men than in men; primarily related to atypical symptoms at
presentations.18 Diabetics are more likely to have atypical
symptoms of myocardial ischemia (dyspnea, fatigue, and
sweating) than non-diabetics, contributing to misdiagnosis of
cardiac ischemia at the time of presentation in these patients.19
Similarly, compared with other locations of myocardial infarc-
tion, inferior location is more likely to present with upper
abdominal rather than precordial discomfort.20
Pre-discharge trans-thoracic echocardiography showed
lower global LV systolic functions (as measured by ejection
fraction) in patients who missed thrombolytic therapy com-
pared with patients who received it (P< 0.05). Similarly, pa-
tients with missed thrombolysis had higher grades of LV
diastolic dysfunctions (as assessed by mitral inﬂow pulsed-
wave Doppler) than patients who received this therapy
(P< 0.05). This is easily understandable in the light of the
beneﬁcial effect of successful thrombolysis on myocardial sal-
vage and preventing irreversible myocardial damage contribut-
ing to both systolic and diastolic dysfunctions.21
Compared with patients who received thrombolytic ther-
apy, patients missing this therapy had higher in-hospital mor-
tality (0.6% versus 6%, respectively, P< 0.05), clinical heart
failure (9% versus 37%, respectively, P< 0.05), and signiﬁ-
cant cardiac dysrhythmias (6% versus 23%, respectively,
P< 0.05).
This study had several limitations. First, the small number
of patients with STEMI, limited the number of features that
could be studied in our multivariable models of factors con-
tributing to failure of receiving thrombolysis. Second, thestudy included only urban public hospitals and no rural hospi-
tals without emergency physicians on site or private hospitals
included, which could inﬂuence the rate of receiving thrombol-
ysis. Third, patients who died outside the hospital, critically ill
patients, and patients with silent myocardial infarction were
not included in the study.
5. Conclusions
In this study, up to 45% of patients with STEMI and no con-
traindication to thrombolytic therapy missed the opportunity
to receive thrombolysis, most likely due to late presentation
or misdiagnosis at the emergency department. Patients with
missed thrombolysis are at higher risk of in-hospital cardiac
death, heart failure, and cardiac dysrhythmias. Urgent com-
munity and physician awareness programs are needed to in-
crease the utilization of this life saving therapy.
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